More than 25,000 people are already participating in global trials of a potential vaccine.
The German regulator, the Paul Ehrlich Institute, has allowed the next phase of testing of an experimental vaccine known as BNT162b2 to begin, BioNTech and its partner Pfizer said in a statement.
The global trials began in July with 120 sites worldwide, and up to 30,000 participants expected to participate.
According to BioNTech, more than 25,000 participants are currently registered. The company hopes to get permission to use BNT162b2 as early as next month.